Montelukast, a cysteine leukotriene receptor antagonist, was found to rescue DA neurons from degeneration via inhibiting microglial activation, reducing p38 MAPK and p53, and decreasing the production of neurotoxic cytokines including TNF-α and IL-1β in a mouse model of PD [171,172]. This evidence concerns the gene IL1B and Parkinson disease.